Govx stock forecast 2025 points to potential volatility as

Govx stock forecast 2025 points to potential volatility as biotech valuations remain sensitive to clinical trial outcomes. Analysts tracking NASDAQ small-cap biotech names suggest GOVX could trade in the $3.20–$5.80 range if upcoming vaccine-related data in late 2024 meets market expectations. Yahoo strives to connect you with the products, services, and businesses you’re looking for. When you search the Web using Yahoo, content on the Search Results Page comes from a variety of sources. The most recent analyst rating on (GOVX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on GeoVax Labs stock, see the GOVX Stock Forecast page . Valuation models in the GOVX stock forecast 2025 incorporate potential milestone payments from licensing deals, estimated at $15–$20 million over the next fiscal year.